hcplive.com Breaking News Headlines Today | Ground News

hcplive.com image

News from hcplive.com

See all of hcplive.com news coverage in one place. Discover how hcplive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 957 headlines reported on by hcplive.com during the past 3 months.

hcplive.com’s aggregated media bias check is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is hcplive.com credible or reliable? Our Factuality score answers both of those questions. When it comes to hcplive.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about hcplive.com

Where is hcplive.com located?hcplive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top hcplive.com News

FDA keeps Mounjaro off shortage list after reevaluation

Diabetes · United States

FDA keeps Mounjaro off shortage list after reevaluation

72% Center coverage: 50 sources

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from the federal drug shortage list amid intense pushback from compounded drug manufacturers. See the Story

Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected

Obesity · Denmark

Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected

44% Center coverage: 36 sources

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply.See the Story

FDA Approves Zepbound as First Drug Treatment for Obstructive Sleep Apnea

FDA · United States

FDA Approves Zepbound as First Drug Treatment for Obstructive Sleep Apnea

67% Center coverage: 30 sources

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision makes it the first drug treatment for the disorder, which affects about 39 million adults in the United States. See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc